Market Closed -
Nyse
Other stock markets
|
5-day change | 1st Jan Change | ||
25.74 USD | -0.35% |
|
-2.94% | -2.98% |
Feb. 07 | AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo | DJ |
Feb. 07 | US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 51.75B | 41.91B | 81.29B | 100B | 58.5B | |||||
Total Revenues | 51.75B | 41.91B | 81.29B | 100B | 58.5B | |||||
Cost of Goods Sold, Total | 10.01B | 8.57B | 30.66B | 34.1B | 23.99B | |||||
Gross Profit | 41.74B | 33.33B | 50.63B | 66.23B | 34.51B | |||||
Selling General & Admin Expenses, Total | 14.1B | 10.89B | 9.56B | 12.2B | 13.84B | |||||
R&D Expenses | 7.98B | 8.88B | 10.52B | 11.43B | 10.68B | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 4.61B | 3.44B | 3.7B | 3.61B | 4.73B | |||||
Other Operating Expenses, Total | 26.7B | 23.2B | 23.78B | 27.24B | 29.25B | |||||
Operating Income | 15.04B | 10.13B | 26.84B | 39B | 5.26B | |||||
Interest Expense, Total | -1.57B | -1.45B | -1.29B | -1.24B | -2.21B | |||||
Interest And Investment Income | 446M | 351M | 202M | 565M | 2.1B | |||||
Net Interest Expenses | -1.13B | -1.1B | -1.09B | -673M | -109M | |||||
Income (Loss) On Equity Invest. | 17M | 298M | 471M | 436M | 505M | |||||
Currency Exchange Gains (Loss) | -172M | - | -192M | -1.15B | 164M | |||||
Other Non Operating Income (Expenses) | 1.31B | 2.29B | 1.88B | 2.62B | 1.28B | |||||
EBT, Excl. Unusual Items | 15.07B | 11.62B | 27.92B | 40.22B | 7.09B | |||||
Restructuring Charges | -1.28B | -859M | -1.36B | -2.02B | -3.33B | |||||
Merger & Related Restructuring Charges | -2M | -528M | - | -200M | -668M | |||||
Gain (Loss) On Sale Of Investments | 8.54B | 546M | 1.34B | -1.27B | 1.59B | |||||
Gain (Loss) On Sale Of Assets | 31M | -237M | 99M | - | 222M | |||||
Asset Writedown | -2.84B | -1.69B | -86M | -421M | -3.02B | |||||
In Process R&D Expenses | - | - | - | -953M | -194M | |||||
Insurance Settlements | 50M | - | - | - | - | |||||
Legal Settlements | -472M | -28M | -182M | -230M | -474M | |||||
Other Unusual Items | -1.42B | -1.32B | -3.42B | -394M | -157M | |||||
EBT, Incl. Unusual Items | 17.68B | 7.5B | 24.31B | 34.73B | 1.06B | |||||
Income Tax Expense | 1.38B | 477M | 1.85B | 3.33B | -1.12B | |||||
Earnings From Continuing Operations | 16.3B | 7.02B | 22.46B | 31.4B | 2.17B | |||||
Earnings Of Discontinued Operations | 4M | 2.63B | -434M | 6M | -15M | |||||
Net Income to Company | 16.3B | 9.65B | 22.02B | 31.41B | 2.16B | |||||
Minority Interest | -29M | -36M | -45M | -35M | -39M | |||||
Net Income - (IS) | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B | |||||
Preferred Dividend and Other Adjustments | 1M | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B | |||||
Net Income to Common Excl. Extra Items | 16.27B | 6.98B | 22.41B | 31.37B | 2.13B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 2.92 | 1.73 | 3.92 | 5.59 | 0.38 | |||||
Basic EPS - Continuing Operations | 2.92 | 1.26 | 4 | 5.59 | 0.38 | |||||
Basic Weighted Average Shares Outstanding | 5.57B | 5.56B | 5.6B | 5.61B | 5.64B | |||||
Net EPS - Diluted | 2.87 | 1.71 | 3.85 | 5.47 | 0.37 | |||||
Diluted EPS - Continuing Operations | 2.87 | 1.24 | 3.93 | 5.47 | 0.37 | |||||
Diluted Weighted Average Shares Outstanding | 5.68B | 5.63B | 5.71B | 5.73B | 5.71B | |||||
Normalized Basic EPS | 1.69 | 1.3 | 3.11 | 4.48 | 0.78 | |||||
Normalized Diluted EPS | 1.65 | 1.28 | 3.05 | 4.38 | 0.77 | |||||
Dividend Per Share | 1.44 | 1.52 | 1.56 | 1.6 | 1.64 | |||||
Payout Ratio | 49.43 | 87.77 | 39.72 | 28.63 | 436.38 | |||||
American Depositary Receipts Ratio (ADR) | 0.25 | 0.25 | 0.25 | 0.25 | 0.25 | |||||
Supplemental Items | ||||||||||
EBITDA | 21.01B | 14.89B | 31.95B | 44.02B | 11.52B | |||||
EBITA | 19.65B | 13.56B | 30.54B | 42.6B | 9.99B | |||||
EBIT | 15.04B | 10.13B | 26.84B | 39B | 5.26B | |||||
EBITDAR | 21.71B | 15.66B | 32.84B | 45.24B | 12.8B | |||||
Total Revenues (As Reported) | - | - | - | - | 58.5B | |||||
Effective Tax Rate - (Ratio) | 7.83 | 6.36 | 7.62 | 9.58 | -105.39 | |||||
Current Domestic Taxes | -1.94B | 429M | 3.38B | 2.72B | 1.19B | |||||
Current Foreign Taxes | 2.9B | 1.52B | 2.77B | 4.37B | 1.14B | |||||
Total Current Taxes | 958M | 1.95B | 6.14B | 7.09B | 2.33B | |||||
Deferred Domestic Taxes | 1.35B | -1.18B | -4.34B | -3.58B | -2.79B | |||||
Deferred Foreign Taxes | -919M | -292M | 48M | -183M | -652M | |||||
Total Deferred Taxes | 427M | -1.47B | -4.29B | -3.76B | -3.44B | |||||
Normalized Net Income | 9.39B | 7.23B | 17.4B | 25.11B | 4.39B | |||||
Interest Capitalized | 88M | 96M | 108M | 124M | 160M | |||||
Non-Cash Pension Expense | 206M | -76M | -2.14B | -247M | -508M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.6B | 1.8B | 2B | 2.8B | 3.7B | |||||
Selling and Marketing Expenses | 2.6B | 1.8B | 2B | 2.8B | 3.7B | |||||
Research And Development Expense From Footnotes | 8.65B | 9.4B | 13.83B | 11.43B | 10.68B | |||||
Net Rental Expense, Total | 700M | 773M | 888M | 1.22B | 1.28B | |||||
Imputed Operating Lease Interest Expense | 195M | 202M | 240M | 329M | 424M | |||||
Imputed Operating Lease Depreciation | 505M | 571M | 648M | 889M | 859M | |||||
Stock-Based Comp., Other (Total) | 738M | 776M | 1.2B | 891M | 545M | |||||
Total Stock-Based Compensation | 738M | 776M | 1.2B | 891M | 545M |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 1.3B | 1.78B | 1.94B | 416M | 2.85B | |||||
Short Term Investments | 8.52B | 10.44B | 29.12B | 22.32B | 9.84B | |||||
Trading Asset Securities, Total | 53M | 18M | 4M | - | - | |||||
Total Cash And Short Term Investments | 9.88B | 12.24B | 31.07B | 22.73B | 12.69B | |||||
Accounts Receivable, Total | 8.72B | 7.93B | 11.48B | 10.95B | 11.18B | |||||
Other Receivables | 3.34B | 3.26B | 4.27B | 3.58B | 3.98B | |||||
Total Receivables | 12.07B | 11.19B | 15.74B | 14.53B | 15.16B | |||||
Inventory | 8.28B | 8.05B | 9.06B | 8.98B | 10.19B | |||||
Deferred Tax Assets Current | - | - | - | - | - | |||||
Other Current Assets, Total | 2.57B | 3.59B | 3.82B | 5.02B | 5.3B | |||||
Total Current Assets | 32.8B | 35.07B | 59.69B | 51.26B | 43.33B | |||||
Gross Property Plant And Equipment | 32.07B | 30.1B | 32.8B | 34.45B | 37.91B | |||||
Accumulated Depreciation | -16.79B | -14.81B | -15.07B | -15.17B | -16.04B | |||||
Net Property Plant And Equipment | 15.28B | 15.29B | 17.72B | 19.28B | 21.86B | |||||
Long-term Investments | 20.41B | 20.38B | 21.54B | 14.93B | 15.38B | |||||
Goodwill | 58.65B | 49.58B | 49.21B | 51.38B | 67.78B | |||||
Other Intangibles, Total | 35.37B | 28.47B | 25.15B | 43.37B | 64.9B | |||||
Deferred Tax Assets Long-Term | 900M | 900M | 1.6B | 4.8B | 1.8B | |||||
Other Long-Term Assets, Total | 4.07B | 4.54B | 6.57B | 12.2B | 11.44B | |||||
Total Assets | 167B | 154B | 181B | 197B | 227B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 4.22B | 4.31B | 5.58B | 6.81B | 6.71B | |||||
Accrued Expenses, Total | 6.59B | 6.51B | 7.67B | 8.32B | 9.22B | |||||
Short-term Borrowings | 14.73B | 701M | 605M | 385M | 8.1B | |||||
Current Portion of Long-Term Debt | 1.46B | 2B | 1.64B | 2.57B | 2.27B | |||||
Current Portion of Leases | 276M | 321M | 449M | 620M | 527M | |||||
Current Income Taxes Payable | 980M | 1.05B | 1.27B | 1.59B | 2.35B | |||||
Unearned Revenue Current, Total | 9M | 957M | 4.02B | 2.52B | 2.7B | |||||
Deferred Tax Liability Current | - | - | - | - | - | |||||
Other Current Liabilities | 9.04B | 10.07B | 21.44B | 19.33B | 15.92B | |||||
Total Current Liabilities | 37.3B | 25.92B | 42.67B | 42.14B | 47.79B | |||||
Long-Term Debt | 35.96B | 37.13B | 36.2B | 33.2B | 61.81B | |||||
Long-Term Leases | 1.05B | 1.11B | 2.51B | 2.6B | 2.63B | |||||
Unearned Revenue Non Current | - | - | - | - | - | |||||
Pension & Other Post Retirement Benefits | 6.76B | 5.41B | 3.72B | 2.25B | 2.17B | |||||
Deferred Tax Liability Non Current | 5.58B | 4.06B | 349M | 1.02B | 640M | |||||
Other Non Current Liabilities | 17.4B | 17.12B | 18.56B | 20.08B | 22.17B | |||||
Total Liabilities | 104B | 90.76B | 104B | 101B | 137B | |||||
Preferred Stock Convertible | 17M | - | - | - | - | |||||
Total Preferred Equity | 17M | - | - | - | - | |||||
Common Stock, Total | 468M | 470M | 473M | 476M | 478M | |||||
Additional Paid In Capital | 87.43B | 88.67B | 90.59B | 91.8B | 92.63B | |||||
Retained Earnings | 97.67B | 96.77B | 103B | 126B | 118B | |||||
Treasury Stock | -111B | -111B | -111B | -114B | -114B | |||||
Comprehensive Income and Other | -11.64B | -11.69B | -5.9B | -8.3B | -7.96B | |||||
Total Common Equity | 63.13B | 63.24B | 77.2B | 95.66B | 89.01B | |||||
Minority Interest | 303M | 235M | 262M | 256M | 274M | |||||
Total Equity | 63.45B | 63.47B | 77.46B | 95.92B | 89.29B | |||||
Total Liabilities And Equity | 167B | 154B | 181B | 197B | 227B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 5.55B | 5.58B | 5.62B | 5.62B | 5.65B | |||||
ECS Total Common Shares Outstanding | 5.53B | 5.57B | 5.62B | 5.62B | 5.65B | |||||
Book Value / Share | 11.41 | 11.36 | 13.74 | 17.03 | 15.77 | |||||
Tangible Book Value | -30.9B | -14.81B | 2.85B | 916M | -43.67B | |||||
Tangible Book Value Per Share | -5.58 | -2.66 | 0.51 | 0.16 | -7.73 | |||||
Total Debt | 53.47B | 41.27B | 41.4B | 39.38B | 75.33B | |||||
Net Debt | 43.59B | 29.03B | 10.32B | 16.64B | 62.64B | |||||
Debt Equivalent of Unfunded Proj. Benefit Obligation | 5.4B | 4.4B | 1.73B | 1.18B | 561M | |||||
Debt Equivalent Oper. Leases | 5.6B | 6.18B | 7.1B | 9.74B | 10.26B | |||||
Minority Interest, Total (Incl. Fin. Div) | 303M | 235M | 262M | 256M | 274M | |||||
Equity Method Investments, Total | 17.13B | 16.86B | 16.47B | 11.03B | 11.64B | |||||
Account Code - Inventory Valuation | 6 | 6 | 6 | 6 | 6 | |||||
Inventories - Raw Materials, Total | 790M | 738M | 994M | 859M | 1.01B | |||||
Inventories - Work In Process, Total | 4.74B | 4.43B | 4.42B | 5.52B | 5.69B | |||||
Inventories - Finished Goods, Total | 2.75B | 2.88B | 3.64B | 2.6B | 3.5B | |||||
Land - (BS) | 516M | 444M | 423M | 368M | 353M | |||||
Buildings, Total | 10.07B | 9.02B | 9B | 8.83B | 9.05B | |||||
Machinery, Total | 17.21B | 15.69B | 16.71B | 17.37B | 19.66B | |||||
Full Time Employees | 88.3K | 78.5K | 79K | 83K | 88K | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 527M | 508M | 492M | 449M | 470M |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B | |||||
Depreciation & Amortization - CF | 1.36B | 1.32B | 1.4B | 1.42B | 1.52B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 4.61B | 3.44B | 3.7B | 3.61B | 4.73B | |||||
Depreciation & Amortization, Total | 5.97B | 4.76B | 5.1B | 5.03B | 6.26B | |||||
(Gain) Loss From Sale Of Asset | - | - | - | - | - | |||||
(Gain) Loss on Sale of Investments - (CF) | -8.23B | -6M | - | - | - | |||||
Asset Writedown & Restructuring Costs | 2.99B | 2.07B | 363M | 586M | 3.44B | |||||
Stock-Based Compensation (CF) | 718M | 756M | 1.18B | 872M | 525M | |||||
Net Cash From Discontinued Operations | - | 3.82B | -343M | - | 15M | |||||
Other Operating Activities, Total | -1.1B | -6.33B | -8.51B | -4.14B | -1.48B | |||||
Change In Accounts Receivable | -742M | -1.25B | -3.81B | 261M | 347M | |||||
Change In Inventories | -1.05B | -736M | -1.12B | 592M | -1.17B | |||||
Change In Accounts Payable | -564M | 353M | 1.24B | 1.19B | -300M | |||||
Change in Other Net Operating Assets | -1.68B | 1.36B | 16.5B | -6.5B | -1.05B | |||||
Cash from Operations | 12.59B | 14.4B | 32.58B | 29.27B | 8.7B | |||||
Capital Expenditure | -2.18B | -2.25B | -2.71B | -3.24B | -3.91B | |||||
Cash Acquisitions | -10.86B | - | - | -23B | -43.43B | |||||
Sale (Purchase) of Intangible assets | -418M | -539M | - | - | - | |||||
Investment in Marketable and Equity Securities, Total | 9.3B | -1.67B | -19.52B | 6.68B | 15.24B | |||||
Other Investing Activities, Total | 206M | 192M | -318M | 3.77B | -180M | |||||
Cash from Investing | -3.94B | -4.27B | -22.55B | -15.78B | -32.28B | |||||
Short Term Debt Issued, Total | 19.01B | 12.35B | - | 3.89B | 7.69B | |||||
Long-Term Debt Issued, Total | 4.94B | 5.22B | 997M | - | 30.83B | |||||
Total Debt Issued | 23.95B | 17.57B | 997M | 3.89B | 38.52B | |||||
Short Term Debt Repaid, Total | -8.38B | -26.33B | -96M | -4.11B | -3M | |||||
Long-Term Debt Repaid, Total | -6.81B | -4B | -2B | -3.3B | -2.57B | |||||
Total Debt Repaid | -15.18B | -30.33B | -2.1B | -7.41B | -2.57B | |||||
Issuance of Common Stock | 394M | 425M | - | - | - | |||||
Repurchase of Common Stock | -8.86B | - | - | -2B | - | |||||
Common Dividends Paid | - | -8.44B | -8.73B | -8.98B | -9.25B | |||||
Common & Preferred Stock Dividends Paid | -8.04B | - | - | - | - | |||||
Common & Preferred Stock Dividends Paid | -8.04B | -8.44B | -8.73B | -8.98B | -9.25B | |||||
Other Financing Activities, Total | -735M | 11.12B | 16M | -335M | -632M | |||||
Cash from Financing | -8.48B | -9.65B | -9.82B | -14.83B | 26.07B | |||||
Foreign Exchange Rate Adjustments | -32M | -8M | -59M | -165M | -40M | |||||
Miscellaneous Cash Flow Adjustments | -1M | - | - | - | - | |||||
Net Change in Cash | 125M | 475M | 159M | -1.52B | 2.45B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 1.59B | 1.64B | 1.47B | 1.44B | 2.22B | |||||
Cash Income Tax Paid (Refund) | 3.66B | 3.15B | 7.43B | 7.87B | 3.15B | |||||
Levered Free Cash Flow | 18.42B | 10.5B | 30.86B | 24.96B | 1.02B | |||||
Unlevered Free Cash Flow | 19.4B | 11.41B | 31.66B | 25.73B | 2.4B | |||||
Change In Net Working Capital | -5.89B | -2.33B | -11.29B | 1.32B | 3.78B | |||||
Net Debt Issued / Repaid | 8.76B | -12.76B | -1.1B | -3.52B | 35.94B |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.75 | 3.93 | 10 | 12.87 | 1.55 | |||||
Return on Total Capital | 8.44 | 5.71 | 15.01 | 19.18 | 2.19 | |||||
Return On Equity % | 25.62 | 11.06 | 31.87 | 36.22 | 2.35 | |||||
Return on Common Equity | 25.72 | 11.06 | 31.92 | 36.29 | 2.31 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 80.66 | 79.54 | 62.28 | 66.02 | 58.99 | |||||
SG&A Margin | 27.25 | 25.99 | 11.77 | 12.16 | 23.65 | |||||
EBITDA Margin % | 40.61 | 35.52 | 39.3 | 43.88 | 19.69 | |||||
EBITA Margin % |